Top Story Today
Roche Liked Its First Chinese ADC Deal So Much, It Came Back for a $15 Billion Encore
One year after licensing a single antibody-drug conjugate from China's Hansoh Pharmaceutical for $1.45 billion, Roche just went back and bought access to the entire platform. The new deal is worth over $15 billion in potential milestones (plus $400 million upfront), roughly a tenfold escalation. Instead of licensing one molecule, Roche will now propose cancer targets and Hansoh will build custom ADCs using its proprietary linker-payload technology. It's the difference between buying a painting and commissioning an artist to decorate your whole house.
Why it matters: Chinese biotechs now account for nearly 90% of global ADC licensing deals by count. Roche's massive repeat partnership shows that Western pharma will keep writing billion-dollar checks for Chinese drug innovation, geopolitical tensions or not.
Read more →The IBD Arms Race
AbbVie Built a Drug Designed to Beat Its Own Blockbuster. It Worked.
AbbVie's combo therapy ABBV-466 outperformed Skyrizi, its own blockbuster, in a Phase 2a Crohn's disease trial. By week 24, the combination hit 40.5% endoscopic remission versus 22.4% for Skyrizi alone. The logic: if someone's going to cannibalize your best-selling drug, better you than a competitor. Safety looked clean across all arms, clearing a key early hurdle for combination therapy in IBD.
Read more →Gilead's UC Pill Just Posted Remission Rates Nearly 4x Placebo
Gilead's oral ulcerative colitis drug emvistegrast hit 31% clinical remission at 12 weeks versus 8% on placebo, with side effects comparable to sugar pills. The pill targets the same pathway as Takeda's injectable blockbuster Entyvio but comes in a form patients actually prefer: something you swallow at home. A late-stage study is planned for 2027.
Read more →Deals and M&A
Viatris Drops $1.65 Billion (and a 45% Premium) to Break Up With Generics
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, paying a 45% premium for the non-opioid pain specialist and its flagship product EXPAREL ($575 million in 2025 sales). It's the generics giant's biggest move yet in a pivot toward specialty pharma, though analysts note the company paid "full price" for a business that's 79% dependent on one product.
Read more →Shionogi Bets $2 Billion on Diseases Most Doctors Have Never Seen
The Japanese infectious disease giant is paying $2 billion cash for IntraBio, a rare disease company with a drug (Aqneursa) already approved for two ultra-rare neurological conditions. Analysts estimate peak sales around $1 billion, making the price roughly 2x peak revenue; nearly a bargain by orphan drug standards. It's a bold pivot from antibiotics into neurodegenerative disease.
Read more →Clinical Breakthroughs and Funding
Roche's Failed Schizophrenia Drug Just Aced a Pivotal Trial for Sun Allergies
Disc Medicine's bitopertin, a molecule Roche abandoned after it flopped in schizophrenia, swept every endpoint in a pivotal Phase 3 trial for erythropoietic protoporphyria, a rare disorder that makes sunlight excruciating. Patients gained 12 extra pain-free hours per month in daylight, and blood toxin levels dropped 41%. One caveat: dizziness hit 50% of the treatment group. Disc Medicine plans to resubmit an NDA by end of 2026 after receiving a Complete Response Letter from the FDA earlier this year.
Read more →$135 Million to Vaccinate People Against Cancer Before It Starts
Nouscom closed an oversubscribed $135 million Series D to fund a pivotal trial of NOUS-209, an off-the-shelf cancer vaccine for Lynch syndrome carriers who are genetically destined to develop colorectal cancer. No therapeutic cancer vaccine for a solid malignant tumor has won FDA approval in over a decade. The money funds one make-or-break trial to prove cancer interception actually works.
Read more →